Table 1.
Study sample characteristics
| Reference group n = 1402 | Arterial Disease group n = 502 | Venous Disease group n = 195 | |
|---|---|---|---|
| Sex (females) | 60.5% (848) | 36.7% (184) | 63.6% (124) |
| Age(years) | 49.3 ± 9.8 | 63.8 ± 8.5 | 61.3 ± 10.1 |
| BMI (kg/m2) | 24.2 (22.2/26.3) | 28.8 (25.7/32.2) | 28.6 (25.5/31.5) |
| Cardiovascular risk factors | |||
| Diabetes | 0% (0) | 20.1% (101) | 9.7% (19) |
| Obesity | 0% (0) | 41.2% (207) | 36.9% (72) |
| Smoking | 22.5% (316) | 16.2% (81) | 11.3% (22) |
| Arterial hypertension | 0% (0) | 72.5% (364) | 59.0% (115) |
| Dyslipidemia | 0% (0) | 40.1% (201) | 30.8% (60) |
| Family history of MI/Stroke | 31.1% (436) | 43.6% (219) | 43.6% (85) |
| Comorbidities | |||
| CAD | 0% (0) | 46.5% (217) | 9.1% (17) |
| MI | 0% (0) | 30.4% (151) | 5.2% (10) |
| Stroke | 0% (0) | 18.5% (92) | 6.2% (12) |
| AF | 0% (0) | 9.2% (45) | 6.2% (12) |
| PAD | 0% (0) | 40.2% (200) | 26.6% (51) |
| CHF | 0% (0) | 6.2% (31) | 6.7% (13) |
| DVT | 0% (0) | 14.3% (71) | 99.0% (193) |
| PE | 0% (0) | 1.6% (8) | 5.7% (11) |
| Therapy | |||
| Anti-coagulant agentsa | 1.8% (25) | 61.0% (305) | 35.4% (69) |
| Oral contraceptive therapy | 12.5% (174) | 6.4% (32) | 9.7% (19) |
| Hormonal replacement therapy | 5.5% (77) | 5.6% (28) | 11.3% (22) |
Abbreviations: BMI body mass index, MI myocardial infarction, AF atrial fibrillation, PAD peripheral artery disease, CAD coronary artery disease, CHF congestive heart failure, DVT deep venous thrombosis, PE pulmonary embolism
aATC codes: B01AA (vitamin K antagonists), B01AB (heparin group), B01AE (direct thrombin inhibitors), B01AF (direct factor Xa inibitors), B01AX (other antithrombotic agents)